EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

External Validation of Pre‐Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy

Gabriel Adrian iD, Andre Haraldsson Änghede, Lachlan McDowell, Maria Gebre-Medhin

Head & Neck · 2026

DOI: 10.1002/hed.70315 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Head & Neck, 2026. Verfasst von Gabriel Adrian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden. Hauptthemen laut MEDLINE: Tumor Burden, Chemoradiotherapy, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fru Berta Kamprads Stiftelse, Svenska Sällskapet för Medicinsk Forskning, Tegger Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary tumor volume (GTVp) is a key prognostic factor in oropharyngeal squamous cell carcinoma (OPSCC) treated with radiotherapy. We aimed to externally validate this association and assess its relevance in other head and neck sites.

Methods

Patients from the RADCURE dataset were analyzed using Cox regression for local failure, progression‐free survival (PFS), and overall survival (OS). Subgroup analyses included HPV status, chemotherapy use, and separate evaluations for hypopharyngeal and laryngeal cancers. Model performance was assessed using the concordance index (C‐index).

Results

Among 1286 OPSCC patients, increasing GTVp was associated with a higher risk of local failure and reduced PFS and OS, consistent across HPV and chemotherapy subgroups. Similar associations were observed in hypopharyngeal ( n = 157) and laryngeal ( n = 803) cancers. Model performance was strong (C‐index up to 0.82).

Conclusion

Primary tumor volume is a robust prognostic factor across head and neck cancer sites, supporting risk stratification in curative radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor BurdenChemoradiotherapyHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckHumansPrognosisFemaleMaleMiddle AgedAgedOropharyngeal Neoplasms

Stichwörter der Autor:innen

hypopharynx cancerlarynx canceroropharyngeal squamous cell carcinomaprognostic factortumor volumevalidation

Autor:innen und Institutionen

  • Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
  • Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia.
  • Department of Clinical Sciences Lund, Division of Oncology, Lund University, Lund, Sweden.

ORCID-Profile: Gabriel Adrian

Förderung

  • Fru Berta Kamprads Stiftelse
  • Svenska Sällskapet för Medicinsk Forskning
  • Tegger Foundation

Zitieren

APA

Adrian, G., Änghede, A. H., McDowell, L., & Gebre-Medhin, M. (2026). External Validation of Pre‐Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy. Head & Neck. https://doi.org/10.1002/hed.70315

Vancouver

Adrian G, Änghede AH, McDowell L, Gebre-Medhin M. External Validation of Pre‐Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy. Head & Neck. 2026. doi:10.1002/hed.70315

BibTeX
@article{Adrian2026,
  author = {Adrian, Gabriel and Änghede, Andre Haraldsson and McDowell, Lachlan and Gebre-Medhin, Maria},
  title = {External Validation of Pre‐Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy},
  journal = {Head & Neck},
  year = {2026},
  doi = {10.1002/hed.70315}
}
Kostenlos starten →